Cargando…
A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease
Among a group of 310 natural antiviral natural metabolites, our team identified three compounds as the most potent natural inhibitors against the SARS-CoV-2 main protease (PDB ID: 5R84), M(pro). The identified compounds are sattazolin and caprolactin A and B. A validated multistage in silico study w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369012/ https://www.ncbi.nlm.nih.gov/pubmed/35955547 http://dx.doi.org/10.3390/ijms23158407 |
_version_ | 1784766325162246144 |
---|---|
author | Elkaeed, Eslam B. Eissa, Ibrahim H. Elkady, Hazem Abdelalim, Ahmed Alqaisi, Ahmad M. Alsfouk, Aisha A. Elwan, Alaa Metwaly, Ahmed M. |
author_facet | Elkaeed, Eslam B. Eissa, Ibrahim H. Elkady, Hazem Abdelalim, Ahmed Alqaisi, Ahmad M. Alsfouk, Aisha A. Elwan, Alaa Metwaly, Ahmed M. |
author_sort | Elkaeed, Eslam B. |
collection | PubMed |
description | Among a group of 310 natural antiviral natural metabolites, our team identified three compounds as the most potent natural inhibitors against the SARS-CoV-2 main protease (PDB ID: 5R84), M(pro). The identified compounds are sattazolin and caprolactin A and B. A validated multistage in silico study was conducted using several techniques. First, the molecular structures of the selected metabolites were compared with that of GWS, the co-crystallized ligand of M(pro), in a structural similarity study. The aim of this study was to determine the thirty most similar metabolites (10%) that may bind to the M(pro) similar to GWS. Then, molecular docking against M(pro) and pharmacophore studies led to the choice of five metabolites that exhibited good binding modes against the M(pro) and good fit values against the generated pharmacophore model. Among them, three metabolites were chosen according to ADMET studies. The most promising M(pro) inhibitor was determined by toxicity and DFT studies to be caprolactin A (292). Finally, molecular dynamics (MD) simulation studies were performed for caprolactin A to confirm the obtained results and understand the thermodynamic characteristics of the binding. It is hoped that the accomplished results could represent a positive step in the battle against COVID-19 through further in vitro and in vivo studies on the selected compounds. |
format | Online Article Text |
id | pubmed-9369012 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93690122022-08-12 A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease Elkaeed, Eslam B. Eissa, Ibrahim H. Elkady, Hazem Abdelalim, Ahmed Alqaisi, Ahmad M. Alsfouk, Aisha A. Elwan, Alaa Metwaly, Ahmed M. Int J Mol Sci Article Among a group of 310 natural antiviral natural metabolites, our team identified three compounds as the most potent natural inhibitors against the SARS-CoV-2 main protease (PDB ID: 5R84), M(pro). The identified compounds are sattazolin and caprolactin A and B. A validated multistage in silico study was conducted using several techniques. First, the molecular structures of the selected metabolites were compared with that of GWS, the co-crystallized ligand of M(pro), in a structural similarity study. The aim of this study was to determine the thirty most similar metabolites (10%) that may bind to the M(pro) similar to GWS. Then, molecular docking against M(pro) and pharmacophore studies led to the choice of five metabolites that exhibited good binding modes against the M(pro) and good fit values against the generated pharmacophore model. Among them, three metabolites were chosen according to ADMET studies. The most promising M(pro) inhibitor was determined by toxicity and DFT studies to be caprolactin A (292). Finally, molecular dynamics (MD) simulation studies were performed for caprolactin A to confirm the obtained results and understand the thermodynamic characteristics of the binding. It is hoped that the accomplished results could represent a positive step in the battle against COVID-19 through further in vitro and in vivo studies on the selected compounds. MDPI 2022-07-29 /pmc/articles/PMC9369012/ /pubmed/35955547 http://dx.doi.org/10.3390/ijms23158407 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Elkaeed, Eslam B. Eissa, Ibrahim H. Elkady, Hazem Abdelalim, Ahmed Alqaisi, Ahmad M. Alsfouk, Aisha A. Elwan, Alaa Metwaly, Ahmed M. A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease |
title | A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease |
title_full | A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease |
title_fullStr | A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease |
title_full_unstemmed | A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease |
title_short | A Multistage In Silico Study of Natural Potential Inhibitors Targeting SARS-CoV-2 Main Protease |
title_sort | multistage in silico study of natural potential inhibitors targeting sars-cov-2 main protease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369012/ https://www.ncbi.nlm.nih.gov/pubmed/35955547 http://dx.doi.org/10.3390/ijms23158407 |
work_keys_str_mv | AT elkaeedeslamb amultistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT eissaibrahimh amultistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT elkadyhazem amultistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT abdelalimahmed amultistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT alqaisiahmadm amultistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT alsfoukaishaa amultistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT elwanalaa amultistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT metwalyahmedm amultistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT elkaeedeslamb multistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT eissaibrahimh multistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT elkadyhazem multistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT abdelalimahmed multistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT alqaisiahmadm multistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT alsfoukaishaa multistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT elwanalaa multistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease AT metwalyahmedm multistageinsilicostudyofnaturalpotentialinhibitorstargetingsarscov2mainprotease |